[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596700":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":62,"collaborators":26,"id":64,"slug":26,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":26,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Center for Sight Las Vegas","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Comparator Systane Artificial Tears","PLACEBO_COMPARATOR","Comparator arm is Systane artificial tears",[13],"Drug: Systane",{"label":15,"type":16,"description":17,"interventionNames":18},"FDA Approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%)","ACTIVE_COMPARATOR","FDA approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%) is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",[19],"Drug: Rocklatan (netarsudil 0.02% and latanoprost 0.005%)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rocklatan (netarsudil 0.02% and latanoprost 0.005%)","Additional intraocular eye pressure lowering post-Hydrus",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Systane","Placebo Comparator (artificial tears)",[9],[32],{"name":33,"affiliation":34,"role":35},"Medical Director, Medical Doctor","Center For Sight","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Clinical Research Manager","CONTACT","702-724-2005","jodi.kennedy@c4slv.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":26},"Clinical Research Coordinator","702-724-2067",[46],{"facility":47,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Center for Sight","Las Vegas","Nevada","89145","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-115.13722,36.17497,{"lat":57,"lon":56},[60,61],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":43,"role":39,"phone":26,"phoneExt":26,"email":26},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100596700",false,"NCT07048886","Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","Inclusion Criteria:\n\n* Age 40 years and older\n* Subjects who have mild to moderate Open Angle Glaucoma (OAG)\n* Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \\> 3 months prior to screening and within the last 2 years\n* Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)\n* Unmedicated or washed out IOP range between 16-26 mmHg\n\nExclusion Criteria:\n\n* History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation\n* Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery\n* Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome\n* Severe Open Angle Glaucoma\n* Narrow angles, other angle abnormalities or angle closure glaucoma\n* Allergy or intolerance to Rocklatan\n* History of corneal edema, or corneal disease or dystrophy\n* Current or history of intra-ocular infection or inflammation\n* History of retinal diseases that could affect diagnostic testing\n* Anticipated use of intra-ocular or topical steroids not associated with the study protocol\n* Pregnant, breastfeeding or planning to become pregnant during the study\n* Any condition in the opinion in the investigator that would potentially confound the results of the study","ALL","40 Years",{"count":72,"type":73},68,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.",[79],"Primary Open Angle Glaucoma",[79,81],"Rocklatan","NOT_YET_RECRUITING","2025-06-30",{"date":85,"type":86},"2025-07-03","ACTUAL",{"date":88,"type":73},"2025-07-15",{"date":90,"type":73},"2026-12-31",{"name":5,"class":6},1]